{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug-induced+Parkinsonism",
    "query": {
      "condition": "Drug-induced Parkinsonism"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 15,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug-induced+Parkinsonism&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T15:57:46.526Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02361255",
      "title": "Degenerative Nigrostriatal Dysfunction in Drug-induced Parkinsonism",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Secondary Parkinsonism",
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "no intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Corporal Michael J. Crescenz VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "40 Years to 89 Years"
      },
      "enrollment_count": 40,
      "start_date": "2015-02",
      "completion_date": "2019-04",
      "has_results": false,
      "last_update_posted_date": "2018-04-05",
      "last_synced_at": "2026-07-22T15:57:46.526Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02361255"
    },
    {
      "nct_id": "NCT02598973",
      "title": "Effect of Exercise in Parkinsonism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Parkinson's Disease",
        "Drug-induced Parkinsonism"
      ],
      "interventions": [
        {
          "name": "Exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "40 Years to 89 Years"
      },
      "enrollment_count": 9,
      "start_date": "2016-02-01",
      "completion_date": "2022-01-31",
      "has_results": true,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-07-22T15:57:46.526Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02598973"
    },
    {
      "nct_id": "NCT01092065",
      "title": "Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "AFQ056 with L-dopa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 23,
      "start_date": "2010-03",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2020-12-23",
      "last_synced_at": "2026-07-22T15:57:46.526Z",
      "location_count": 4,
      "location_summary": "Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana + 1 more",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01092065"
    },
    {
      "nct_id": "NCT04857359",
      "title": "Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Parkinson Disease",
        "Dyskinesia, Drug-Induced",
        "Dyskinesias"
      ],
      "interventions": [
        {
          "name": "Dipraglurant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Addex Pharma S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 25,
      "start_date": "2021-08-06",
      "completion_date": "2022-08-15",
      "has_results": false,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-07-22T15:57:46.526Z",
      "location_count": 41,
      "location_summary": "Phoenix, Arizona • Fresno, California • Irvine, California + 38 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04857359"
    },
    {
      "nct_id": "NCT03495024",
      "title": "Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Tobacco Smoking",
        "Tardive Dyskinesia",
        "Parkinsonism"
      ],
      "interventions": [
        {
          "name": "Varenicline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corporal Michael J. Crescenz VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2019-01-01",
      "completion_date": "2020-06-30",
      "has_results": false,
      "last_update_posted_date": "2019-03-22",
      "last_synced_at": "2026-07-22T15:57:46.526Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03495024"
    },
    {
      "nct_id": "NCT02761707",
      "title": "Biomarkers in Neural Disorders",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parkinson's Disease",
        "Alzheimer's Disease",
        "Progressive Supranuclear Palsy",
        "Essential Tremor",
        "Multiple System Atrophy",
        "Drug Induced Parkinson's Disease",
        "Diffuse Lewy Body Disease",
        "Myasthenia Gravis",
        "Spinal Cord Injuries"
      ],
      "interventions": [
        {
          "name": "Electrical Brainstem Responses",
          "type": "OTHER"
        },
        {
          "name": "Olfactory Tests",
          "type": "OTHER"
        },
        {
          "name": "Visual Deprivation",
          "type": "OTHER"
        },
        {
          "name": "Peripheral Nerve Stimulation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 54,
      "start_date": "2016-06",
      "completion_date": "2019-07-16",
      "has_results": false,
      "last_update_posted_date": "2019-07-18",
      "last_synced_at": "2026-07-22T15:57:46.526Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02761707"
    },
    {
      "nct_id": "NCT03944447",
      "title": "Outcomes Mandate National Integration With Cannabis as Medicine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Pain",
        "Chronic Pain Syndrome",
        "Chronic Pain Due to Injury",
        "Chronic Pain Due to Trauma",
        "Fibromyalgia",
        "Seizures",
        "Hepatitis C",
        "Cancer",
        "Crohn Disease",
        "HIV/AIDS",
        "Multiple Sclerosis",
        "Traumatic Brain Injury",
        "Sickle Cell Disease",
        "Post Traumatic Stress Disorder",
        "Tourette Syndrome",
        "Ulcerative Colitis",
        "Glaucoma",
        "Epilepsy",
        "Inflammatory Bowel Diseases",
        "Parkinson Disease",
        "Amyotrophic Lateral Sclerosis",
        "Chronic Traumatic Encephalopathy",
        "Anxiety",
        "Depression",
        "Insomnia",
        "Autism",
        "Opioid-use Disorder",
        "Bipolar Disorder",
        "Covid19",
        "SARS-CoV Infection",
        "COVID-19",
        "Corona Virus Infection",
        "Coronavirus"
      ],
      "interventions": [
        {
          "name": "Cannabis, Medical",
          "type": "DRUG"
        },
        {
          "name": "RYAH-Medtech Inhaler",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "OMNI Medical Services, LLC",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 200000,
      "start_date": "2018-12-01",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-06-02",
      "last_synced_at": "2026-07-22T15:57:46.526Z",
      "location_count": 17,
      "location_summary": "Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03944447"
    },
    {
      "nct_id": "NCT01474421",
      "title": "Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyskinesias",
        "Drug-induced"
      ],
      "interventions": [
        {
          "name": "AQW051",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 71,
      "start_date": "2011-09-15",
      "completion_date": "2013-02-21",
      "has_results": false,
      "last_update_posted_date": "2020-12-24",
      "last_synced_at": "2026-07-22T15:57:46.526Z",
      "location_count": 4,
      "location_summary": "Sacramento, California • Manhasset, New York • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01474421"
    },
    {
      "nct_id": "NCT01789047",
      "title": "Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Parkinson's Disease",
        "Drug Induced Dyskinesia"
      ],
      "interventions": [
        {
          "name": "Topiramate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Amantadine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "30 Years to 90 Years"
      },
      "enrollment_count": 42,
      "start_date": "2013-03",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-07-22T15:57:46.526Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01789047"
    },
    {
      "nct_id": "NCT01173731",
      "title": "Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease",
        "Dyskinesia, Drug-Induced",
        "Levodopa"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 66,
      "start_date": "2010-10",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2020-12-23",
      "last_synced_at": "2026-07-22T15:57:46.526Z",
      "location_count": 3,
      "location_summary": "Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01173731"
    }
  ]
}